Targeting Apoptosis to Overcome Chemotherapy Resistance

Dogan, Eda; Kara, Hale Güler; Kosova, Buket; Çetintaş, Vildan Bozok

doi:10.36255/exon-publications.metastasis.chemotherapy-resistance

Cited by 14 publications

(11 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…and ABCC1), 27 anti-apoptotic (e.g., BCL2 and MCL1) 28 or DNA repair genes (e.g., ERCC1 and MLH1) 29 would be involved in the resistance.…”

Section: Discussionmentioning

confidence: 99%

Association of immune‐related expression profile with sensitivity to chemotherapy in esophageal squamous cell carcinoma

Tsukamoto,

Kurogi,

Fujishima

et al. 2023

Cancer Science

View full text Add to dashboard Cite

Neoadjuvant chemotherapy (NAC) followed by surgery is one of the standard therapeutic approaches in Japan for patients with locally advanced esophageal carcinoma. Recently, the JCOG1109 study revealed that NAC with docetaxel, cisplatin and 5‐fluorouracil (5‐FU) (DCF‐NAC) is superior to NAC with cisplatin and 5‐FU, and has now become the standard preoperative chemotherapy. Using a microarray system, we have previously investigated the expression profiles of endoscopic biopsy samples from patients with esophageal squamous cell carcinoma (ESCC) before DCF‐NAC (preNAC) and identified 17 molecules as biomarkers predictive of a pathologically complete response to DCF‐NAC. Here, we re‐grouped our previous dataset based on the histopathological response grade with the addition of several microarray profiles and conducted a re‐analysis using bioinformatic web tools including DAVID, GSEA, UALCAN, and CIBERSORTx. We identified 204 genes that were differentially expressed between the highly resistant and sensitive groups. Some of these differentially expressed genes (DEGs) were related to the immune response and showed higher expression in the sensitive group. UALCAN showed that high expression of 28 of the top 50 DEGs was associated with a favorable prognosis (p < 0.25), and that this reached a significant (p < 0.05) level for 18 of them, suggesting that patients with high expression of these genes might have benefited from chemotherapy and thus had a better outcome. In preNAC biopsy tissues from a DCF‐sensitive case, we demonstrated the presence of cells expressing mRNA for CXCL9, one of the prognosis‐related DEGs. Our results highlight the association of immune‐related expression profile in preNAC ESCC with the DCF‐NAC efficacy.

show abstract

“…and ABCC1), 27 anti-apoptotic (e.g., BCL2 and MCL1) 28 or DNA repair genes (e.g., ERCC1 and MLH1) 29 would be involved in the resistance.…”

Section: Discussionmentioning

confidence: 99%

Association of immune‐related expression profile with sensitivity to chemotherapy in esophageal squamous cell carcinoma

Tsukamoto,

Kurogi,

Fujishima

et al. 2023

Cancer Science

View full text Add to dashboard Cite

show abstract

“…The intrinsic apoptotic pathway uses mitochondria and mitochondrial proteins. The intrinsic pathway is regulated by the Bcl-2 family of proteins [157]. Many apoptotic stimuli result in up-regulation of BH3-only proteins, thereby activating both Bax and Bak.…”

Section: Effect Of Sbg On Apoptosis In Crcmentioning

confidence: 99%

“…Membrane death receptors belong to the TNF receptor superfamily and include tumor necrosis factor-receptor 1 (TNF-R1/DR1), death receptor-4 (DR4) and -5 (DR5), and Fas (Apo-1/CD95/DR2). These receptors are activated by specific ligands, such as Fas ligand (FasL), TNF-α, and TNF-related apoptosisinducing ligand (TRAIL) [157].…”

Section: Effect Of Sbg On Apoptosis In Crcmentioning

confidence: 99%

Therapeutic Potential of Bioactive Components from Scutellaria baicalensis Georgi in Inflammatory Bowel Disease and Colorectal Cancer: A Review

Jang

Kim

2023

IJMS

View full text Add to dashboard Cite

Scutellaria baicalensis Georgi (SBG), an herbal medicine with various biological activities, including anti-inflammatory, anticancer, antiviral, antibacterial, and antioxidant activities, is effective in treatment of colitis, hepatitis, pneumonia, respiratory infections, and allergic diseases. This herbal medicine consists of major active substances, such as baicalin, baicalein, wogonoside, and wogonin. Inflammatory bowel disease (IBD) comprises a group of inflammatory conditions of the colon and small intestine, with Crohn’s disease and ulcerative colitis being the main types. IBD can lead to serious complications, such as increased risk of colorectal cancer (CRC), one of the most common cancers worldwide. Currently, there is no cure for IBD, and its incidence has been increasing over the past few decades. This review comprehensively summarizes the efficacy of SBG in IBD and CRC and may serve as a reference for future research and development of drugs for IBD and cancer treatment.

show abstract

“…TRAIL is a worthy candidate to combine with standard-of-care treatments because it activates different pathways than many existing chemotherapies and radiation. 83 Most chemotherapies rely on the activity of the tumor suppressor p53, but this protein can become inactivated after initial treatment, decreasing the effectiveness of following rounds of chemotherapy. 84 In addition, disruption in p53-mediated apoptosis can result in chemoresistance and tumor progression.…”

Section: Trail-based Therapies With Standard-of-carementioning

confidence: 99%

Current approaches in enhancing TRAIL therapies in glioblastoma

Thang

Mellows

Mercer-Smith

et al. 2023

Neuro-Oncology Advances

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most prevalent, aggressive, primary brain cancer in adults and continues to pose major medical challenges due in part to its high rate of recurrence. Extensive research is underway to discover new therapies that target GBM cells and prevent the inevitable recurrence in patients. The pro-apoptotic protein tumor necrosis factor related apoptosis-inducing ligand (TRAIL) has attracted attention as an ideal anti-cancer agent due to its ability to selectively kill cancer cells with minimal toxicity in normal cells. Although initial clinical evaluations of TRAIL therapies in several cancers were promising, later stages of clinical trial results indicated that TRAIL and TRAIL-based therapies failed to demonstrate robust efficacies due to poor pharmacokinetics, resulting in insufficient concentrations of TRAIL at the therapeutic site. However, recent studies have developed novel ways to prolong TRAIL bioavailability at the tumor site and efficiently deliver TRAIL and TRAIL-based therapies using cellular and nanoparticle vehicles as drug loading cargos. Additionally, novel techniques have been developed to address monotherapy resistance, including modulating biomarkers associated with TRAIL resistance in GBM cells. This review highlights the promising work to overcome the challenges of TRAIL-based therapies with the aim to facilitate improved TRAIL efficacy against GBM.

show abstract

Targeting Apoptosis to Overcome Chemotherapy Resistance

Cited by 14 publications

References 137 publications

Association of immune‐related expression profile with sensitivity to chemotherapy in esophageal squamous cell carcinoma

Association of immune‐related expression profile with sensitivity to chemotherapy in esophageal squamous cell carcinoma

Therapeutic Potential of Bioactive Components from Scutellaria baicalensis Georgi in Inflammatory Bowel Disease and Colorectal Cancer: A Review

Current approaches in enhancing TRAIL therapies in glioblastoma

Contact Info

Product

Resources

About